key: cord-0980604-3bi09t1o authors: Mehta, H.; Handa, S.; Malhotra, P.; Patial, M.; Gupta, S.; Mukherjee, A.; Chatterjee, D.; Takkar, A.; Mahajan, R. title: Erythema nodosum, zoster duplex and pityriasis rosea as possible cutaneous adverse effects of Oxford–AstraZeneca COVID‐19 vaccine: report of three cases from India date: 2021-10-05 journal: J Eur Acad Dermatol Venereol DOI: 10.1111/jdv.17678 sha: a5851b5bb24e56220185adc00829e0a62644b62d doc_id: 980604 cord_uid: 3bi09t1o As a response to the coronavirus disease (COVID-19) pandemic, several vaccines have been developed globally and are being rolled out at a fast pace for public immunization. Drug controller general of India has approved use of CovaxinTM (BBV152, manufactured by Bharat Biotech) and CovishieldTM (Oxford-AstraZeneca COVID-19 vaccine, manufactured by Serum Institute of India) for restricted use in emergency situation.1 We describe three cases of CovishieldTM induced minor cutaneous adverse effects. As a response to the coronavirus disease (COVID-19) pandemic, several vaccines have been developed globally and are being rolled out at a fast pace for public immunization. Drug controller general of India has approved use of Covaxin TM (BBV152, manufactured by Bharat Biotech, Hyderabad, India) and Covishield TM (Oxford-AstraZeneca COVID-19 vaccine, manufactured by Serum Institute of India, Pune, India) for restricted use in emergency situation. 1 We describe three cases of Covishield TM induced minor cutaneous adverse effects. First case was a 25-year-old woman with complaints of lowgrade fever, joint pains and red, and painful nodules over legs and forearm of three days duration. History suggestive of any infection preceding the eruption was denied. She gave history of receiving Covishield 7 days prior to the episode. Cutaneous examination revealed multiple erythematous tender nodules over bilateral shins and forearms (Fig. 1a) . Laboratory evaluation revealed elevated inflammatory markers. SARS-Cov-2 was not detected by reverse transcription (RT)-PCR. An extensive workup to rule out underlying aetiologies of erythema nodosum (EN) was negative. Skin biopsy revealed infiltration of dermal and subcutaneous tissue with lymphomononuclear cells and neutrophils, consistent with erythema nodosum (Fig. 1b) . Patient was treated with topical mometasone cream and oral paracetamol. Dermatological symptoms had resolved completely at follow-up visit after 2 weeks. No recurrence was observed on receiving second dose after 4 weeks. Infections are the most common cause of EN, and this eruption has been described in association with COVID-19 infection as well. 2,3 EN associated with other vaccines has been rarely reported 4 ; however, this is the first report of any COVID-19 vaccine-induced EN to the best of our knowledge. Second case was a 55-year-old man who presented with first episode of herpes zoster of both T10 dermatomes after COVID-19 vaccination (Fig. 1C) . Tzanck smear from the base of blister revealed acantholytic cells and multinucleate giant cells (Fig. 1D) . He gave previous history of varicella and had not been vaccinated against herpes zoster. He reported receiving first dose of Covishield 3 days prior to cutaneous eruption. He denied any history of previous unusual infections or family history of any immune defects. Fasting blood sugar level was 95 mg/dL, and HIV test and COVID-19 RT-PCR were negative. He was prescribed oral valcyclovir 1 g thrice a day for 1 week. Resolution of symptoms was noted on follow-up visit after 2 weeks. Immunomodulation by various vaccines has been reported to result in herpes zoster reactivation previously. 5 A recent observational study reported six cases of herpes zoster reactivation in patients with autoimmune rheumatic diseases. 6 Herpes zoster duplex bilateralis has been reported rarely in immunocompetent adults. 7 Third case was a 24-year-old man with complaints of asymptomatic cutaneous eruption from three days. Examination revealed several well-defined round to oval salmon-coloured papules and plaques up to 3 cm in diameter covered by fine white scales over his trunk, back and axillae (Fig. 2a,b) . Patient reported receiving Covishield 24 h prior to onset of cutaneous lesions. Laboratory evaluation was normal, and COVID-19 RT-PCR was negative. Patient did not consent for skin biopsy. In view of characteristic morphology and supportive dermatoscopic findings (Fig. 2c) , a diagnosis of pityriasis rosea (PR) was made and he was prescribed topical mometasone cream. Further progression of rash could not be monitored as the patient was lost to follow-up. PR-like rash has been reported previously with COVID-19 infection 8 and other COVID-19 mRNA vaccines. 9 A possible explanation is diversion of T cells towards vaccine resulting in reduced control on infectious agents such as HHV-6/7 and their consequent reactivation. 10 Cutaneous adverse effects of Moderna and Pfizer vaccines have been described recently, 6 but similar reports with Covishield are lacking in literature. We report three adverse events temporally related to Oxford-AstraZeneca COVID-19 vaccine. While reactivation of herpes and pityriasis rosea have been described with COVID-19 vaccination before, erythema nodosum has not been reported previously. As these adverse effects were mild and resolved without sequelae, the general population should feel assured about its safety and should be encouraged to adopt vaccination at the earliest. COVID-19 vaccines under trials in India Erythema nodosum as a cutaneous manifestation of COVID-19 infection Cutaneous manifestations in confirmed COVID-19 patients: a systematic review Combined reduced-antigen content tetanus, diphtheria, and acellular pertussis (tdap) vaccine-related erythema nodosum: case report and review of vaccine-associated erythema nodosum Reactivation of herpesvirus infections after vaccinations? Herpes zoster following BNT162b2 mRNA Covid-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: a case series Oxford) 2021; keab345 Herpes zoster duplex bilateralis in immuno-competent patients: report of two cases Pityriasis rosea as a cutaneous manifestation of COVID-19 infection Cutaneous reactions reported after Moderna and Pfizer COVID-19 vaccination: a registrybased study of 414 cases Vaccine-induced pityriasis rosea and pityriasis rosea-like eruptions: a review of the literature An informed consent was given by the patients for publication of the image and clinical details after reading the manuscript. None.